Bioactivity:

Seratrodast (INN), a thromboxane A2 (TXA2) receptor (TP receptor) antagonist, is mainly used in the therapy of asthma. It was the first TP receptor antagonist developed as an anti-asthmatic drug and attained marketing qualification in Japan in 1997.

CAS nr:

112665-43-7

Purity:

98%

Molecular Weight:

354,44

SMILES:

CC1=C(C)C(=O)C(C(CCCCCC(O)=O)c2ccccc2)=C(C)C1=O

Formula:

C22H26O4

Pathway:

GPCR/G Protein,Immunology/Inflammation,Immunology/Inflammation,Metabolism,DNA Damage/DNA Repair,Neuroscience

Target:

Prostaglandin Receptor,Prostaglandin Receptor,COX,PPAR,PPAR,COX